Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1

BACKGROUND: Several predictive biomarkers are currently approved or are under investigation for the selection of patients for checkpoint blockade. Tumor PD-L1 expression is used for stratification of non-small cell lung (NSCLC) patients, with tumor mutational burden (TMB) also being explored with pr...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Immunother Cancer
Main Authors: Smith, Kellie N., Llosa, Nicolas J., Cottrell, Tricia R., Siegel, Nicholas, Fan, Hongni, Suri, Prerna, Chan, Hok Yee, Guo, Haidan, Oke, Teniola, Awan, Anas H., Verde, Franco, Danilova, Ludmila, Anagnostou, Valsamo, Tam, Ada J., Luber, Brandon S., Bartlett, Bjarne R., Aulakh, Laveet K., Sidhom, John-William, Zhu, Qingfeng, Sears, Cynthia L., Cope, Leslie, Sharfman, William H., Thompson, Elizabeth D., Riemer, Joanne, Marrone, Kristen A., Naidoo, Jarushka, Velculescu, Victor E., Forde, Patrick M., Vogelstein, Bert, Kinzler, Kenneth W., Papadopoulos, Nickolas, Durham, Jennifer N., Wang, Hao, Le, Dung T., Justesen, Sune, Taube, Janis M., Diaz, Luis A., Brahmer, Julie R., Pardoll, Drew M., Anders, Robert A., Housseau, Franck
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2019
Assuntos:
Case Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6371497/
https://ncbi.nlm.nih.gov/pubmed/30744692
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-018-0492-x
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados